SCHEMBL535011

SCHEMBL535011

NC1=CC(=O)C=N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18533018 0.61
SCHEMBL5576943 0.60
SCHEMBL1136777 0.53
SCHEMBL21819622 0.52 SLC2A1 (0.36)
Hydrochloric Acid SCHEMBL11511320 0.50 SLC2A1 (0.39)
SCHEMBL4964070 0.49 NSD2 (0.43)
SCHEMBL21819582 0.49 NSD2 (0.43)
Bromide SCHEMBL11511582 0.47 NSD2 (0.42)
SCHEMBL722291 0.46
Benzoquinone SCHEMBL9134802 0.46 ALDH1A1 (0.80)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226309-A1 HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB Synthorx, Inc. (US) 2024-07-11 US disclosed
WO-2024137864-A1 CANCER THERAPY WITH IL-2 CONJUGATES AND CHIMERIC ANTIGEN RECEPTOR THERAPIES Synthorx, Inc. (US) 2024-06-27 WO disclosed
WO-2024136899-A1 CANCER THERAPY WITH IL-2 CONJUGATES AND CHIMERIC ANTIGEN RECEPTOR THERAPIES Synthorx, Inc. (US) 2024-06-27 WO disclosed
US-20240117363-A1 PRODUCTION OF UNNATURAL NUCLEOTIDES USING A CRISPR/CAS9 SYSTEM THE SCRIPPS RESEARCH INSTITUTE 2024-04-11 US disclosed
EP-4346903-A1 HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND PEMBROLIZUMAB Synthorx, Inc. (US) 2024-04-10 EP disclosed
EP-4346904-A1 HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB Synthorx, Inc. (US) 2024-04-10 EP disclosed
EP-4326239-A1 EXTRACELLULAR VESICLES LOADED WITH BIOMOLECULES Spot Biosystems Ltd. (US) 2024-02-28 EP disclosed
US-11879145-B2 Reagents and methods for replication, transcription, and translation in semi-synthetic organisms THE SCRIPPS RESEARCH INSTITUTE (US) 2024-01-23 US disclosed
US-20230416327-A1 IMMUNO ONCOLOGY THERAPIES WITH IL-2 CONJUGATES Synthorx, Inc. (US) 2023-12-28 US disclosed
EP-4291243-A1 LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF Synthorx, Inc. (US) 2023-12-20 EP disclosed
WO-2001012223-A2 METHODS OF MODULATING AN IMMUNE RESPONSE USING IMMUNOSTIMULATORY SEQUENCES AND COMPOSITIONS FOR USE THEREIN DYNAVAX TECHNOLOGIES CORPORATION (US) 2001-02-22 WO disclosed
WO-2001002007-A1 METHOD FOR ENHANCING AN IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2001-01-11 WO disclosed
WO-2000054803-A2 IMMUNOSTIMULATORY NUCLEIC ACIDS AND ANTIGENS PANACEA PHARMACEUTICALS, LLC (US) 2000-09-21 WO disclosed
WO-2000021556-A1 ANTI HIV COMPOSITIONS COMPRISING IMMUNOSTIMULATORY POLYNUCLEOTIDES AND HIV ANTIGENS DYNAVAX TECHNOLOGIES CORPORATION (US) 2000-04-20 WO disclosed
EP-0986572-A2 IMMUNOSTIMULATORY OLIGONUCLEOTIDES, COMPOSITIONS THEREOF AND METHODS OF USE THEREOF Dynavax Technologies Corporation (US) 2000-03-22 EP disclosed
WO-1999062923-A2 IMMUNOSTIMULATORY OLIGONUCLEOTIDES WITH MODIFIED BASES AND METHODS OF USE THEREOF DYNAVAX TECHNOLOGIES CORPORATION (US) 1999-12-09 WO disclosed
EP-0930893-A1 IMMUNOSTIMULATORY POLYNUCLEOTIDE/IMMUNOMODULATORY MOLECULE CONJUGATES The Regents of The University of California (US) 1999-07-28 EP disclosed
WO-1998055495-A2 IMMUNOSTIMULATORY OLIGONUCLEOTIDES, COMPOSITIONS THEREOF AND METHODS OF USE THEREOF DYNAVAX TECHNOLOGIES CORPORATION (US) 1998-12-10 WO disclosed
WO-1998016247-A1 IMMUNOSTIMULATORY POLYNUCLEOTIDE/IMMUNOMODULATORY MOLECULE CONJUGATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-04-23 WO disclosed
CN-1078235-A Medicinal compound LILLY CO ELI (US) 1993-11-10 CN disclosed